Editorial: Novel Approaches to Improve Detection, Differentiation and Treatment in Mood Disorders

Karim Abdel Aziz¹, Andrés Herane-Vives²,³,⁴, Emmanuel Stip⁵,⁶ and Danilo Arnone¹,³*

¹ Department of Psychiatry and Behavioural Science, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, ² Institute of Cognitive Neuroscience, University College London, London, United Kingdom, ³ Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, United Kingdom, ⁴ Center for Integrative Biology, Universidad Mayor, Providencia, Santiago, Chile, ⁵ Institute Universitaire en Santé Mentale de Montréal, Université de Montréal, Montréal, QC, Canada

Keywords: mood disorders, major depressive disorder, clinical differentiation, treatment, bipolar disorder

Editorial of the Research Article

Novel Approaches to Improve Detection, Differentiation and Treatment in Mood Disorders

Mood disorders are a group of common conditions with uncertain disease mechanisms and unsatisfactory treatment outcomes which significantly affect quality of life (1). Refining our understanding of the aetiology of these conditions and improving treatment response are essential next steps to improve outcome. This topic includes research which aims at detection, characterisation and differentiation within mood disorders, with a particular focus on aetiological mechanisms and pathways to improve treatment response.

In relation to the importance of early detection and preventative approaches, Chen X. et al. describe MoodBox, an internet-based psychological intervention designed to improve the psychological well-being of individuals experiencing subclinical depressive symptoms aiming at reducing transition into major depression. The intervention, to be tested in a multicentre, randomised, non-blinded, superiority study intends to compare MoodBox with an online psychoeducation programme and a naturalistic observational group for 8 weeks with a further 1 year follow-up phase.

There is interest in identifying potential novel therapeutic targets in major depression. Psilocybin is a novel approach currently under investigation for treatment refractory major
depression which benefits from psychological assistance (5). The training that therapists receive to support this intervention is important. Tai et al. describe a new manualized evidence-based psychotherapeutic approach to assist psilocybin therapy. The intervention, developed in partnership with different mental health researchers, practitioners and experts across the US, Canada and Europe is approved by the US Food and Drug Administration. Li et al. describe the role of peripheral facial injection of botulinum neurotoxin type A in major depression. Preclinical models suggest that anti-depressant effects might be associated with up-regulation of serotonin levels and expression of brain-derived neurotrophic factor in the hippocampus. Authors conclude that with limitations, clinical data are encouraging and suggest that this therapy is a potential effective and safe intervention for the management of depression. Song et al. investigated antithrombin III (ATIII) as a potential biomarker for the evaluation and prediction of treatment response in major depression. The authors randomised patients to treatment with occipital repetitive transcranial magnetic stimulation (rTMS) or sham treatment for 5 days. The results revealed a reduction in ATIII after occipital rTMS in depressed patients and a relationship between change in ATIII and therapeutic response to occipital rTMS.

Studies evaluating differentiation within mood disorders and between mood disorders and other mental health conditions are particularly important to improve disease specificity at the point of diagnosis and treatment. Ge et al. described a network analysis method to map the presence of anxiety symptoms in individuals with major depression to potentially increase diagnostic precision and target interventions to reduce the occurrence of treatment resistance. Results revealed eight co-occurring symptoms in the network structure. Dong et al. investigated differences in gut microbiota between representative cases of major depressive disorder and general anxiety disorder. The study elucidated a gut-microbiome signature associated with these two conditions that might facilitate differential diagnosis and targeted therapeutic interventions.

In relation to developing cost effective approaches which provide innovative and simple solutions for diagnosis or help to identify those in need of supportive measure or predictors of treatment response, there are several new technologies which have recently been adopted in mental health including computer-based applications (6). Lee et al. provide a literature review of the use of wearable devices and sensors in patients with depression and discuss issues regarding utility, reliability, users’ perspectives and privacy. Wang et al. investigated the association between depression and gait characteristics with the aim to assist the diagnosis of depression by using support vector machine algorithms. The most efficient model they described used time- and frequency-domain features with a very high specificity, suggesting that depression could be effectively recognized through gait analysis.

Finally, the article by Qian et al. investigated the role of chromatin remodelling which included histone acetylation in an animal model of major depression. The authors showed an association between depressive-like behaviours induced by chronic social defeat stress in mice and a decrease in the class II histone deacetylase HDAC7 in the nucleus accumbens. The work suggests that HDAC7 might be a promising therapeutic target for depression.

The work published in this issue adds to recent discoveries in mood disorders and contribute to improve aetiological and detection pathways which offer new opportunities for developing novel treatments (7). Some of the most interesting recent advances in mood disorders include the realisation that epigenetic markers can transmit across generations (8), the validation and consistent replication of structural and functional neuroimaging changes in mood disorders (9–11), new developments in the techniques to analyse co-morbidities at brain level (12), the development of multi-essays serological tests to integrate biological markers with clinical phenotypes (13). Esketamine and more recently Lumaterpene are among the most novel approved new treatments for mood disorders (14, 15), whereas esmethadone (16) and new neuromodulation techniques such as transcranial alternating and direct current stimulation (17, 18) are some of the new approaches under consideration.

In conclusion although mood disorders are complex condition which offer considerable challenges at different levels from the recruitment of research participants (19) to limited knowledge at brain level (20), our understanding of aberrant processes is expanding and new treatments are increareasingly becoming available.

AUTHOR CONTRIBUTIONS

KA, AH-V, and ES contributed to writing of the first and subsequent drafts. DA conceived the idea, contributed to the writing of the manuscript, and supervised the work. All the authors approved the final version of the manuscript.

REFERENCES

1. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. (2013) 43:471–81. doi: 10.1017/S0033291712001511
2. Marvel CL, Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am. (2004) 27:19–36. doi: 10.1016/S0193-953X(03)00106-0
3. Wise T, Radua J, Nortje G, Cleare AJ, Young AH, Arnone D. Voxel-based meta-analytical evidence of structural connectivity in major depression and bipolar disorder. Biol Psychiatry. (2016) 79:293–302. doi: 10.1016/j.biopsych.2015.03.004
4. Cambridge OR, Knight MJ, Mills N, Baune BT. The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: a systematic review. Psychiatry Res. (2018) 269:157–71. doi: 10.1016/j.psychres.2018.08.033
5. Reynolds CF. Psilocybin-assisted supportive psychotherapy in the treatment of major depression—quo vadis? *JAMA Psychiatry*. (2021) 78:476. doi: 10.1001/jamapsychiatry.2020.2901

6. Marshall JM, Dunstan DA, Bartik W. The digital psychiatrist: in search of evidence-based apps for anxiety and depression. *Front Psychiatry*. (2019) 10:831. doi: 10.3389/fpsyt.2019.00831

7. Li Z, Ruan M, Chen J, Fang Y. Major depressive disorder: advances in neuroscience research and translational applications. *Neurosci Bull*. (2021) 37:863–80. doi: 10.1007/s12264-021-00638-3

8. Yeshurun S, Hannan AJ. Transgenerational epigenetic influences of paternal environmental exposures on brain function and predisposition to psychiatric disorders. *Mol Psychiatry*. (2019) 24:536–48. doi: 10.1038/s41380-018-0039-2

9. Arnone D, Job D, Selvaraj S, Abe O, Amico F, Cheng Y, et al. Computational meta-analysis of statistical parametric maps in major depression. *Hum Brain Mapp*. (2016) 37:1393–404. doi: 10.1002/hbm.23108

10. Arnone D. Functional MRI findings, pharmacological treatment in major depression and clinical response. *Prog Neuropsychopharmacol Biol Psychiatry*. (2019) 91:28–37. doi: 10.1016/j.pnpbp.2018.08.004

11. Pezzoli S, Emsell L, Yip SW, Dima D, Giannakopoulos P, Zarei M, et al. Meta-analysis of regional white matter volume in bipolar disorder with replication in an independent sample using coordinates, T-maps, and individual MRI data. *Neurosci Biobehav Rev*. (2018) 84:162–70. doi: 10.1016/j.neubiorev.2017.11.005

12. Fortea L, Albajes-Eizagirre A, Yao Y-W, Soler E, Verdolini N, Hausx AO, et al. Focusing on comorbidity—A novel meta-analytic approach and protocol to disentangle the specific neuroanatomy of co-occurring mental disorders. *Front Psychiatry*. (2022) 12:807839. doi: 10.3389/fpsyt.2021.807839

13. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. *Mol Psychiatry*. (2013) 18:332–9. doi: 10.1038/mp.2011.166

14. McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H, et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. *J Affect Disord*. (2020) 276:576–84. doi: 10.1016/j.jad.2020.06.050

15. Calabrrese JR, Durgan S, Satlin A, Vanover KE, Davis RE, Chen R, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. *Am J Psychiatry*. (2021) 178:1098–106. doi: 10.1176/appi.ajp.202091339

16. Fava M, Stahl S, Pan I, De Martin S, Pappagallo M, Guidetti C, et al. REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. *Am J Psychiatry*. (2021) appi-jp. doi: 10.1176/appi.ajp.2021.21020197

17. Alexander ML, Alagapan S, Lugo CE, Mellin JM, Lustenberger C, Rubinow DR, et al. Double-blind, randomized pilot clinical trial targeting alpha oscillations with transcranial alternating current stimulation (tACS) for the treatment of major depressive disorder (MDD). *Transl Psychiatry*. (2019) 9:106. doi: 10.1038/s41389-019-0439-0

18. Chase HW, Bou dewyn MA, Carter CS, Phillips ML. Transcranial direct current stimulation: a roadmap for research, from mechanism of action to clinical implementation. *Mol Psychiatry*. (2020) 25:397–407. doi: 10.1038/s41380-019-0499-9

19. Wise T, Arnone D, Marwood L, Zahn R, Lythe KE, Young AH. Recruiting for research studies using online public advertisements: examples from research in affective disorders. *Neuropsychiatr Dis Treat*. (2016) 12:279–85. doi: 10.2147/NPD.S90941

20. Wise T, Cleare AI, Herane A, Young AH, Arnone D. Diagnostic and therapeutic utility of neuroimaging in depression: an overview. *Neuropsychiatr Dis Treat*. (2014) 10:1509–22. doi: 10.2147/NPD.S50156

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.